MiNA Therapeutics

Please note: The information displayed on this page might be outdated.
MiNA Therapeutics: Leader in RNA activation (RNAa). RNAa platform address 3,500+ indications, capable of drugging any protein target to increase natural protein production in patients own cells. Validated lipid nanoparticle delivery technology (exclusive license with BioNTech), 50+ targets under evaluation in immuno-oncology and genetic rare disease pipeline, 2 clinical programs (10 expected by 2025), 1 ISS, 15 pre-clinical programs. Lead program MTL-CEPBA, first RNAa therapy to achieve clinical POC, restores CEPBA protein pathway (randomized Ph2 study with sorafenib in 2L HCC has 1Q23 interim/2Q24 final data and potential accelerated approval 2024, Ph1/1b study with MTL-CEBPA+Pembro in advanced solid tumors with primary resistance to anti-PD1). Second RNAa candidate MTL-STING reactivates innate immune responses (1Q23 IND filing). Genetic rare disease portfolio addressing MPS1 Hurler programs (Ph1/2 start 1Q23), complement deficiency, blood disorder. Partnerships with Eli Lilly, Servier ($1.5B+ payments). Key investors – aMoon, Eli Lilly.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Immuno-Oncology, Oncology, Rare Disease
Investment Participation
Series A
Market Cap
Therapeutic Modalities
Platform Technology
84 Wood Lane
London, England W12 0BZ
United Kingdom

Company Participants at Solebury Trout 1x1 Management Access Event 2022

  • Robert Habib, Chief Executive Officer
  • Robin Wright, CFO